|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Capitalization1 |
87 528 | 94 860 | 132 331 | 131 461 | 181 878 | 198 415 | - | - |
Enterprise Value (EV)2 |
102 011 | 109 142 | 144 340 | 143 328 | 206 261 | 220 925 | 216 466 | 210 663 |
P/E ratio |
29,2x | 44,0x | 97,9x | 41,0x | 1 468x | 36,8x | 23,9x | 18,6x |
Yield |
4,05% | 3,74% | 2,78% | 2,80% | 2,44% | 2,34% | 2,46% | 2,55% |
Capitalization / Revenue |
3,90x | 4,29x | 5,43x | 4,94x | 4,86x | 4,54x | 4,24x | 3,87x |
EV / Revenue |
4,54x | 4,94x | 5,92x | 5,38x | 5,51x | 5,05x | 4,63x | 4,10x |
EV / EBITDA |
15,2x | 15,3x | 21,6x | 17,2x | 27,2x | 15,4x | 12,5x | 10,4x |
Price to Book |
5,85x | 7,61x | 10,00x | 8,41x | 4,24x | 4,83x | 4,41x | 3,88x |
Nbr of stocks (in thousands) |
1 265 982 | 1 266 812 | 1 311 913 | 1 312 660 | 1 549 159 | 1 549 464 | - | - |
Reference price (USD) |
69,1 | 74,9 | 101 | 100 | 117 | 126 | 126 | 126 |
Announcement Date |
02/02/2018 | 02/14/2019 | 02/14/2020 | 02/11/2021 | 02/10/2022 | - | - | - |
1 GBP in Million 2 USD in Million |
|
|
Income Statement Evolution (Annual data) |
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Net sales1 |
22 465 | 22 090 | 24 384 | 26 617 | 37 417 | 43 737 | 46 788 | 51 325 |
EBITDA1 |
6 713 | 7 140 | 6 686 | 8 311 | 7 586 | 14 344 | 17 256 | 20 269 |
Operating profit (EBIT)1 |
6 855 | 5 672 | 6 436 | 7 340 | 9 928 | 14 067 | 16 386 | 18 977 |
Operating Margin |
30,5% | 25,7% | 26,4% | 27,6% | 26,5% | 32,2% | 35,0% | 37,0% |
Pre-Tax Profit (EBT)1 |
2 227 | 1 993 | 1 548 | 3 916 | -265 | 5 254 | 9 887 | 12 384 |
Net income1 |
3 001 | 2 155 | 1 335 | 3 196 | 112 | 5 307 | 8 200 | 10 374 |
Net margin |
13,4% | 9,76% | 5,47% | 12,0% | 0,30% | 12,1% | 17,5% | 20,2% |
EPS2 |
2,37 | 1,70 | 1,03 | 2,44 | 0,08 | 3,42 | 5,26 | 6,76 |
Dividend per Share2 |
2,80 | 2,80 | 2,80 | 2,80 | 2,87 | 2,94 | 3,10 | 3,21 |
Announcement Date |
02/02/2018 | 02/14/2019 | 02/14/2020 | 02/11/2021 | 02/10/2022 | - | - | - |
1 USD in Million 2 USD |
|
|
Income Statement Evolution (Quarterly data) |
|
Fiscal Period: December
|
2019 Q4 |
2020 Q1 |
2020 Q2 |
2020 Q3 |
2020 Q4 |
2021 Q1 |
2021 Q2 |
2021 Q3 |
2021 Q4 |
2022 Q1 |
2022 Q2 |
2022 Q3 |
2022 Q4 |
2023 Q1 |
2023 Q2 |
Net sales1 |
6 664 | 6 354 | 6 275 | 6 578 | 7 410 | 7 320 | 8 220 | 9 866 | 12 011 | 11 390 | 10 589 | 10 748 | 11 246 | 11 157 | 11 225 |
EBITDA1 |
2 220 | 2 061 | 1 994 | 1 972 | 2 284 | 2 692 | 1 880 | 1 114 | 1 900 | 2 187 | 4 630 | 3 251 | 4 419 | - | - |
Operating profit (EBIT)1 |
1 545 | 1 854 | 1 792 | 1 795 | 1 899 | 2 524 | 1 805 | 2 281 | 3 318 | 3 961 | 3 410 | 3 525 | 3 247 | - | - |
Operating Margin |
23,2% | 29,2% | 28,6% | 27,3% | 25,6% | 34,5% | 22,0% | 23,1% | 27,6% | 34,8% | 32,2% | 32,8% | 28,9% | - | - |
Pre-Tax Profit (EBT)1 |
240 | 935 | 961 | 853 | 1 167 | 1 608 | 764 | -2 001 | -636 | 553 | 942 | 1 297 | 1 444 | - | - |
Net income1 |
313 | 780 | 756 | 648 | 1 012 | 1 561 | 550 | -1 652 | -347 | 386 | 1 375 | 1 531 | 2 063 | - | - |
Net margin |
4,70% | 12,3% | 12,0% | 9,85% | 13,7% | 21,3% | 6,69% | -16,7% | -2,89% | 3,39% | 13,0% | 14,2% | 18,3% | - | - |
EPS2 |
0,24 | 0,59 | 0,58 | 0,49 | 0,78 | 1,19 | 0,42 | -1,10 | -0,22 | 0,25 | 0,69 | 0,93 | 1,25 | - | - |
Dividend per Share |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date |
02/14/2020 | 04/29/2020 | 07/30/2020 | 11/05/2020 | 02/11/2021 | 04/30/2021 | 07/29/2021 | 11/12/2021 | 02/10/2022 | 04/29/2022 | - | - | - | - | - |
1 USD in Million 2 USD |
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Net Debt1 |
14 483 | 14 282 | 12 009 | 11 867 | 24 383 | 22 509 | 18 051 | 12 248 |
Net Cash position1 |
- | - | - | - | - | - | - | - |
Leverage (Debt / EBITDA) |
2,16x | 2,00x | 1,80x | 1,43x | 3,21x | 1,57x | 1,05x | 0,60x |
Free Cash Flow1 |
2 252 | 1 575 | 1 990 | 3 838 | 4 872 | 7 913 | 10 714 | 12 818 |
ROE (Net Profit / Equities) |
36,4% | 32,0% | 35,6% | 36,7% | 27,5% | 25,6% | 28,4% | 30,4% |
Shareholders' equity1 |
8 250 | 6 742 | 3 752 | 8 704 | 407 | 20 704 | 28 834 | 34 176 |
ROA (Net Profit / Asset) |
4,77% | 7,07% | 2,19% | 4,99% | 8,77% | 5,23% | 9,73% | 11,6% |
Assets1 |
62 940 | 30 480 | 61 015 | 64 053 | 1 277 | 101 504 | 84 263 | 89 669 |
Book Value Per Share2 |
11,8 | 9,84 | 10,1 | 11,9 | 27,7 | 26,0 | 28,5 | 32,5 |
Cash Flow per Share2 |
2,82 | 2,07 | 2,28 | 3,66 | 4,18 | 7,24 | 9,23 | 10,5 |
Capex1 |
1 326 | 1 043 | 979 | 961 | 1 091 | 2 027 | 2 015 | 2 148 |
Capex / Sales |
5,90% | 4,72% | 4,01% | 3,61% | 2,92% | 4,63% | 4,31% | 4,18% |
Announcement Date |
02/02/2018 | 02/14/2019 | 02/14/2020 | 02/11/2021 | 02/10/2022 | - | - | - |
1 USD in Million 2 USD |
|
| |
|
|
AstraZeneca says its COVID shot still has role despite global glut |
Capitalization (GBP) |
162 166 903 600 |
Capitalization (USD) |
198 604 954 625 |
Net sales (USD) |
37 417 000 000 |
Number of employees |
83 100 |
Sales / Employee (USD) |
450 265 |
Free-Float |
96,4% |
Free-Float capitalization (GBP) |
156 292 769 627 |
Free-Float capitalization (USD) |
191 410 933 618 |
Avg. Exchange 20 sessions (USD) |
20 254 393 167 |
Average Daily Capital Traded |
12,5% |
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
|